UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Korean pharmaceuticals fail to invalidate Invokana patent
  • By Marian Chu
  • Published 2018.06.28 17:58
  • Updated 2018.06.28 17:58
  • comments 0

A three-year-long trial to invalidate the patent for Janssen’s diabetes drug Invokana (ingredient: canaglifozin) came to an end as the Intellectual Property Trial and Appeal Board dismissed it Friday.

The patent invalidation claim for the patent titled “Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene” filed by five domestic pharmaceuticals in April 2015 was dismissed last week.

Inist Biopharmaceutical and Jeil Pharmaceutical aimed to invalidate claims 1, 4, and 7 of the patent while NaviPharm, Huons, and Intro Biopharma aimed to invalidate claims 1, 4, 5, and 7.

The firms originally planned to pad up their diabetes lineup by invalidating the patent in 2015, according to an industry source, which has been put on hold with the recent dismissal.

Invokana is a once-daily SGLT2 inhibitor used to treat type 2 diabetes in adults. Janssen Korea had gained approval for the drug in April 2014 but the company noted that it would not be launching the therapy in the domestic market.

“Janssen Korea has received approval for the drug but did not file for reimbursement considering the diabetes therapies on the domestic market. There is no plan to launch the drug,” a Janssen Korea official said.

yjc@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Marian Chu
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top